AEterna Zentaris (NASDAQ:AEZS) is a small cap drug development company. Like many drug development companies, it has had its share of success and failures over the years. However, the company now appears to be significantly undervalued when compared to the pipeline that it has in development. With the company expected to file an NDA soon and initiating another Phase III trial, the next year or so will provide a multitude of interesting catalysts that should help to drive share price growth. Coupled with the company's financial position, this share price increase should be sustainable and should be able to provide significant returns for long term oriented investors.
AEZS-130 is a test developed by AEterna for the diagnosis...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|